[Mutagenesis of the human histamine H1 receptor and design of new antihistamine agents]. 1996

E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
UCB S.A. Secteur Pharma, Drug Discovery, Chemin du Foriest, Belgique.

The binding cavity of histamine and histamine antagonists is explored using site directed mutagenesis of the human histamine H1 receptor and the amino acids involved in ligand binding are identified. Whereas Asp107 and Phe199 are important for both agonists and antagonists, two additional amino acids (Asn198 and Trp103) are required for efficient histamine binding. The binding site of antagonists is best defined as resulting from a strong ionic bond to Asp107, an orthogonal interaction between one of the aromatic rings with Phe199, and probably a hydrophobic interaction between the second aromatic ring and the lipophilic amino acids of the upper part of TMIV and TMV. This is consistent with structure-activity data of most described antagonists.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011969 Receptors, Histamine H1 A class of histamine receptors discriminated by their pharmacology and mode of action. Most histamine H1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (From Biochem Soc Trans 1992 Feb;20(1):122-5) H1 Receptor,Histamine H1 Receptors,H1 Receptors,Histamine H1 Receptor,Receptors, H1,H1 Receptor, Histamine,H1 Receptors, Histamine,Receptor, H1,Receptor, Histamine H1
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
July 1990, The American review of respiratory disease,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
September 2003, Pharmacological research,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
April 2005, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
November 1998, The Biochemical journal,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
May 1983, Drug and therapeutics bulletin,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
November 2009, Molecular pharmacology,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
October 2004, The Journal of pharmacology and experimental therapeutics,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
June 1980, European journal of pharmacology,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
May 1994, Biochemical and biophysical research communications,
E Differding, and M Gillard, and N Moguilevsky, and F Varsalona, and M Noyer, and J Daliers, and S Goldstein, and M Neuwels, and M A Lassoie, and J P Guillaume, and M Bascour, and A Bollen, and J P Hénichart
September 2016, Pharmacological research,
Copied contents to your clipboard!